Literature DB >> 3162928

Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus.

L K Vujcic1, D H Shepp, M Klutch, M A Wells, R M Hendry, A E Wittek, L Krilov, G V Quinnan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3162928     DOI： 10.1093/infdis/157.5.1047

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  13 in total

1.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

2.  Infection of nonlymphoid cells by human immunodeficiency virus type 1 or type 2.

Authors:  K Ikeuchi; S Kim; R A Byrn; S R Goldring; J E Groopman
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.

Authors:  P F Zhang; X Chen; D W Fu; J B Margolick; G V Quinnan
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Authors:  R A Byrn; I Sekigawa; S M Chamow; J S Johnson; T J Gregory; D J Capon; J E Groopman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells.

Authors:  J M Molina; D T Scadden; C Amirault; A Woon; E Vannier; C A Dinarello; J E Groopman
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.

Authors:  G J Gorse; S E Frey; F K Newman; R B Belshe
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

7.  Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.

Authors:  S Y Kim; R Byrn; J Groopman; D Baltimore
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.

Authors:  D J Medina; G D Hsiung; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Factors affecting cellular tropism of human immunodeficiency virus.

Authors:  S Kim; K Ikeuchi; J Groopman; D Baltimore
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

10.  Lack of a negative influence on viral growth by the nef gene of human immunodeficiency virus type 1.

Authors:  S Kim; K Ikeuchi; R Byrn; J Groopman; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.